4 months ago

Covid: Oxford-AstraZeneca jab protection against South Africa variant 'limited', study suggests

Covid: Oxford-AstraZeneca jab protection against South Africa variant 'limited', study suggests Covid: Oxford-AstraZeneca jab protection against South Africa variant 'limited', study suggestsPublished4 minutes agoSharecloseShare pageCopy linkAbout sharingRelated Topics

  • Coronavirus pandemic
  • Chief Pharmacist Richard Harrison with the Oxford-AstraZeneca coronavirus vaccine at Askham Bar park-and-ride in Yorkimage copyrightPA Media

    Early trials suggest the Oxford-AstraZeneca Covid vaccine offers limited protection against mild disease caused by the South Africa variant.

    But the firm said it believed the vaccine could protect against severe disease caused by the more transmissible coronavirus variant.

    The preliminary findings from a small study of more than 2,000 people have not yet been peer-reviewed.

    More than 100 cases of the South Africa variant have been found in the UK.

  • When will I get the coronavirus vaccine?
  • How worrying are the new variants?
  • South Africa coronavirus variant: What's the risk?
  • Five reasons to be (cautiously) hopeful on Covid
  • The preliminary findings, first reported by the Financial Times and confirmed by AstraZeneca, suggest the vaccine offers limited protection against mild and moderate disease caused by the variant.

    The study is due to be published on Monday.

    A spokesman for AstraZeneca said they had not yet been able to properly establish whether the jab would prevent severe disease and hospitalisation caused by the South Africa variant because those involved in the study had predominantly been young, healthy adults.

    But the company expressed confidence that the vaccine would offer protection against serious cases, because it created neutralising antibodies similar to those of other coronavirus vaccines.

    The University of Oxford told Reuters news agency it was working with AstraZeneca to "optimise" the pipeline in vaccine production if it needed to adapt to a change in the virus.

    It has said a new vaccine to work against mutated versions of the virus could be ready to deploy in the autumn if needed.

    Dr Michael Head, a senior research fellow in global health at Southampton University, said that if the Oxford-AstraZeneca vaccine was less protective against mild disease but prevented severe disease this would "still be a pretty good outcome".

    "I don't think we need to be too alarmed by [the reported findings] as yet but we do need to see the full study to work out what the implications really are," he told the BBC.

    Banner image reading 'more about coronavirus'
  • LOOK-UP TOOL: How many cases in your area?
  • OXFORD JAB: What is the Oxford-AstraZeneca vaccine?
  • SYMPTOMS: What are they and how to guard against them?
  • QUARANTINE: Will I need to self-isolate in a hotel?
  • Banner

    It comes after the company on Saturday said its vaccine provided good protection against the variant first discovered in Kent, which is now dominant in the UK.

    Current vaccines were designed around earlier versions of coronavirus, but scientists believe they should still work against the new ones, although it is not yet clear how well against different mutations.

    Experts say vaccines could be redesigned and tweaked to be a better match for new variants in a matter or weeks or months if necessary.

    Chart showing the number of first vaccine doses received in the UK1px transparent line
  • Meanwhile, workplace Covid testing is being offered to more companies in England and GPs will be paid an additional £10 by the NHS for every housebound patient they vaccinate
  • Surge testing is being rolled out in more areas of England to help control and suppress the spread of new variants, including in parts of Worcestershire, the PR9 postcode area of Sefton, Merseyside, and areas in Bristol and South Gloucestershire.
  • The UK government is aiming to offer all over-50s a coronavirus jab by May, with 15 million people in priority groups vaccinated by 15 February.
  • As of Friday more than 11.4 million people had received a first dose.
  • The latest figures also showed another 828 people in the UK have died within 28 days of a positive Covid test, and there were a further 18,262 cases.
  • Around the BBC - Sounds
  • THE THURSDAY MURDER CLUB: Escape with Richard Osman's bestselling crime novel...
  • RADIO 1'S CHILL MIX: Soothing musical vibes to soundtrack your weekend in lockdown
  • Around the BBC footer - Sounds

    Related Topics

  • AstraZeneca
  • Coronavirus pandemic
  • Coronavirus vaccines
  • Vaccination
  • South Africa
  • University of Oxford
  • More on this story

  • Vaccine chief 'optimistic' about over-50s May goal

    Published5 hours ago
  • UK finds more virus with 'concerning' mutations

    Published4 days ago
  • Oxford-AZ vaccine 'effective against Kent variant'

    Published1 day ago
  • Pfizer vaccine 'works' against key variant mutation

    Published8 January
  • Moderna vaccine appears to work against variants

    Published25 January
  • Five reasons to be (cautiously) hopeful on Covid

    Published1 day ago
  • Original source : https://www.bbc.co.uk/news/uk-55967767

    #vacci #agai1 #varia #avirus #Africa #Oxford #disease #Covid #sugges #cases
    Please login to add comments